Guardant Health (GH) PT Raised to $60 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GH Hot Sheet
Price: $175.00 --0%
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Guardant Health (NASDAQ: GH) to $60.00 (from $55.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Guardant Health adds former Dexcom CEO Kevin Sayer to its board
- Varonis Systems (VRNS) PT Lowered to $49.75 at Cantor Fitzgerald
- Booking Holdings (BKNG) PT Lowered to $200 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
